Related Experiment Video
Updated: Apr 20, 2026
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
Published on: November 13, 2012
A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry,
Joseph J Grudzinski1, Benjamin Titz1, Kevin Kozak2
1Cellectar Biosciences, Inc., Madison, WI, United States of America; Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America.
Introduction:
(131)I-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therapeutic radioisotope. The primary aim of this phase 1 study was to determine the administered radioactivity expected to deliver 400 mSv to the bone marrow. The secondary aims were to determine the pharmacokinetic (PK) and safety profiles of (131)I-CLR1404.
Methods:
Eight subjects with refractory or relapsed advanced solid tumors were treated with a single injection of 370 MBq of (131)I-CLR1404. Whole body planar nuclear medicine scans were performed at 15-35 minutes, 4-6, 18-24, 48, 72, 144 hours, and 14 days post injection. Optional single photon emission computed tomography imaging was performed on two patients 6 days post injection. Clinical laboratory parameters were evaluated in blood and urine. Plasma PK was evaluated on (127)I-CLR1404 mass measurements. To evaluate renal clearance of (131)I-CLR1404, urine was collected for 14 days post injection. Absorbed dose estimates for target organs were determined using the RADAR method with OLINDA/EXM software.
Results:
Single administrations of 370 MBq of (131)I-CLR1404 were well tolerated by all subjects. No severe adverse events were reported and no adverse event was dose-limiting. Plasma (127)I-CLR1404 concentrations declined in a bi-exponential manner with a mean t½ value of 822 hours. Mean Cmax and AUC(0-t) values were 72.2 ng/mL and 15753 ng • hr/mL, respectively. An administered activity of approximately 740 MBq is predicted to deliver 400 mSv to marrow.
Conclusions:
Preliminary data suggest that (131)I-CLR1404 is well tolerated and may have unique potential as an anti-cancer agent.
Trial Registration:
ClinicalTrials.gov NCT00925275.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019